TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: gout flare days
Endpoint domain: Adverse events/effects
Primary endpoint: Mean serum zinc concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: biomarkers associated with cardiovascular morbidity and mortality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of varying patient position
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Comfort for patients
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: performance time of laparoscopic phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total time of the entire surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: mean improvement in anagen ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for 10-item visual analogue format (10VAF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ease of use of 10-item visual analogue format (10VAF)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Response variability of 10-item visual analogue format (10VAF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presumed bacteriologic eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative IPSS values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative OAB-q values
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: plasma levels of quercetin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QSU scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RSBI at 30-minute SBT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in RSBI (ΔRSBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse outcomes in patients with left ventricular ejection fraction <= 40%
Endpoint domain: Adverse events/effects
Primary endpoint: periodic limb movements of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: maximum increase in dBP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: whole-body iron absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: proportion of quitters who are smoking at 24 months postquit
Endpoint domain: Mortality/survival
Primary endpoint: sperm cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: actively motile sperm cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: normal sperm cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: YKL-40 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severe diabetic retinopathy (DR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Recovery from stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in body temperature (Tgi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to spontaneous eye opening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to handgrip on verbal command
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 14-day composite major adverse cardiac events rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TIMI flow grades and TIMI myocardial perfusion grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of PANSS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total score of the functional questionnaires
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Asthma Control Questionnaire symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV₁
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of asthma exacerbations
Endpoint domain: Adverse events/effects
Primary endpoint: 800-m performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in solids content of sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in surface tension of sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in contact angle of sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: combined mortality and morbidity events
Endpoint domain: Mortality/survival
Primary endpoint: Inability to dorsiflex the ankle past -5°
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nonsevere first-step pain (≤7 on ordinal scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heel valgus in relaxed stance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of recommended targets for waist girth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Achievement of recommended targets for blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Achievement of recommended targets for high density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall IQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reading achievement scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregiver-reported attention and aggression problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiovascular events (CVEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost-effectiveness of screening for albuminuria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: pregnancy and live birth rates
Endpoint domain: Mortality/survival
Primary endpoint: mean propofol concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time until sufficient sedation to perform DISE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diclofenac requirements
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Ventricular dyssynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cure rate at day 14
Endpoint domain: Mortality/survival
Primary endpoint: communication score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction with treatment results
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Difference in mentalis rhytids between Botox and placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood DAO levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: LPS and IL-6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cumulative percentage of patients successfully converted to sinus rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dc shock energy requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Technical success of external cardioversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications related to mechanical ventilation
Endpoint domain: Adverse events/effects
Primary endpoint: Total costs for the intensive care unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Occurrence of PCP
Endpoint domain: Adverse events/effects
Primary endpoint: Moderate-to-severe coughing during inhalations
Endpoint domain: Adverse events/effects
Primary endpoint: MLHFQ score change
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Average number of steps completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time per step
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of behavioral distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: breakaway strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukocytopenia and granulocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Infections and neutropenic fever
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor responses (CR and PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in attitudes toward snus
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: favourable treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AMH decrease rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: VAS scores of tourniquet pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal intensity of propofol-induced local pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PP release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: arrhythmia free rate at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight loss (kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body fat percentage loss (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical activity levels improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PACU recovery time
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in regional cerebral blood flow (CBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of oxidative stress and inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: distance driven on excursions from home
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intentions to receive HPV vaccine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: glucose mean incremental area under the curve (IAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin mean incremental area under the curve (IAUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CCK concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Need for ongoing support for spirometry interpretation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: gains in performance on knowledge measures
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum glucose concentration changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of smooth tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Median time to corticosteroid-sparing effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbohydrate oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported motor ability improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: plasma HIV-1 RNA <50 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median CD4 increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Frequency of reaching full working length (WL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Corneal sensation recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial PYY(3‐36) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to return of T1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to return of T25
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TOF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Overall effective rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronic hypotony prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chronically elevated IOP prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of PHE growth
Endpoint domain: Mortality/survival
Primary endpoint: Poor functional outcomes
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: requirement for intravenous fat emulsion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Apgar and NACS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of eyes requiring retreatment
Endpoint domain: Adverse events/effects
Primary endpoint: biologically verified abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Procedure-related pain at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Identification of fetal growth restriction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Improved perinatal outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: probability to remain in remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lack of therapeutic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: lack of endoscopic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Homeostatic model insulin resistance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower urinary tract symptoms score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: prevalence of Aggregatibacter actinomycetemcomitans, Treponema denticola, and Tannerella forsythia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in liver histology score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: 90-day readmission risk
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of invasive fungal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Cost of antifungal therapy
Endpoint domain: Resource use
Primary endpoint: Fractional uptake of 99mTc-DMSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: ABC score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of healing of medium-sized rotator cuff tears
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion showing stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Onset Latency (SOL) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immune response measured by IFN-gamma(+)CD8(+) T cells generation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccination response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection site reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of DRNC and VCUG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Development of cholelithiasis
Endpoint domain: Adverse events/effects
Primary endpoint: median patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived task load
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Pharmacodynamic exposures for susceptible bacteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quantity of cancer coverage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Indinavir AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indinavir Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Indinavir Cmin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of systemic interleukin-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction of systemic interleukin-8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Retention of platelet/leukocyte coaggregates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Progression-free disease at 9 months (PD9)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 180-days adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: perinatal survival
Endpoint domain: Mortality/survival
Primary endpoint: Absolute thrombocytopenia
Endpoint domain: Mortality/survival
Primary endpoint: Relative thrombocytopenia
Endpoint domain: Mortality/survival
Primary endpoint: Absolute platelet count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Wrinkle appearance improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability of cosmetic regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Menstrual blood loss (MBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Occurrence of menorrhagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: improvements in subjective and objective variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total food intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Segmental body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adipokine secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV1 change from pre-dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TDI score
Endpoint domain: Life impact
Endpoint subdomain: Dyspnoea
Primary endpoint: SGRQ improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Episodes of poor asthma control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and acceptability
Endpoint domain: Adverse events/effects
Primary endpoint: duration of analgesic effect after the first dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time course of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse drug-related effects
Endpoint domain: Adverse events/effects
Primary endpoint: Thrombomodulin plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Probability of antibiotic usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean change in anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean pain reduction at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intelligence
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Problem behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptability of the wait-listed trial design
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Satisfaction of joining the study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intention to remain in the study
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: % Body Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical Fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in hepatic encephalopathy (HE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adenoma occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Advanced lesion occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Incidence of laboratory-confirmed influenza illness (LCII)
Endpoint domain: Adverse events/effects